Drug Search Results
More Filters [+]


Alternative Names: nesiritide, natrecor
Latest Update: 2024-03-05
Latest Update Note: Clinical Trial Update

Product Description

Nesiritide (Natrecor) is a recombinant form of human B-type (brain) natriuretic peptide that has beneficial vasodilatory, natriuretic, diuretic and neurohormonal effects. The drug is administered intravenously for the management of patients with decompensated congestive heart failure (CHF). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12487622/)

Mechanisms of Action: GUC Agonist

Novel Mechanism: No

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Colombia | Dominican Republic | Slovenia | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nesiritide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events